Clinical Trial Update: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating mirvetuximab soravtansine plus bevacizumab versus bevacizumab alone as maintenance therapy in platinum-sensitive ovarian,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Elahere (mirvetuximab soravtansine)

Snippet

Sponsor: AbbVie | Conditions: Ovarian Cancer, Peritoneal Cancer | Phase 3 | Status: RECRUITING